<< China Yongxin Pharmaceuticals reports financial results for third-quarter ended September 30, 2009 | Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Ελληνικά | Русский | Svenska | Polski

Key drivers in Denmark's pharmaceutical markets

Published on December 10, 2009 at 9:43 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/590919/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Denmark" report to their offering.

This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Executive Summary

The size of the pharmaceutical market in Denmark is estimated to be US$3.9 billion in 2009, equal to US$711 per capita. The primary care sector constitutes nearly three quarters of the total market size. The market is expected to expand by 8.0% per annum between 2009 and 2014. By 2014, the market is estimated to be worth US$6.4 billion, equal to US$1,134 per capita.

Denmark has a stable political system and a stable economy. However, Denmark is likely to be affected by the global economic downturn, with GDP real growth expected to fall to -3.5% in 2009, according to figures from the Economist Intelligence Unit, and gradually rising to reach a real growth of 2.0% in 2014.

Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long-standing balance of trade surplus, which was in excess of US$4.7 billion in 2008. Between 2004 and 2008, imports increased by a CAGR of 11.9% to US$3.2 billion, while exports increased by a CAGR of 10.5% to US$7.9 billion.

Healthcare expenditure has continued its steady growth in the past few years, increasing by 7.1% to reach DKK118.3 billion (US$21.7 billion) in 2007, with private expenditure accounting for around 16% of the total.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading